Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury
Evidence-based recommendations on the Peristeen transanal irrigation system for people with bowel dysfunction
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta
In development [GID-DG10034] Expected publication date: 30 September 2020
In development [GID-DG10035] Expected publication date: 26 August 2020
In development [GID-DG10028] Expected publication date: 22 April 2020
In development [GID-DG10023] Expected publication date: TBC
In development [GID-DG10029] Expected publication date: 08 July 2020
In development [GID-DG10033] Expected publication date: 29 July 2020
In development [GID-MT530] Expected publication date: 01 June 2020
In development [GID-MT536] Expected publication date: TBC
In development [GID-MT533] Expected publication date: 06 July 2020
In development [GID-MT532] Expected publication date: TBC
In development [GID-MT531] Expected publication date: TBC
In development [GID-MT534] Expected publication date: TBC
In development [GID-MT538] Expected publication date: TBC
In development [GID-MT527] Expected publication date: 30 January 2020
In development [GID-MT526] Expected publication date: TBC
In development [GID-MT539] Expected publication date: 01 September 2020
In development [GID-MT537] Expected publication date: 06 October 2020
In development [GID-MT529] Expected publication date: 06 April 2020
In development [GID-MT528] Expected publication date: 11 March 2020
This guidance has been updated and replaced by NICE guideline NG47.
This guideline has been updated and replaced by NICE guideline NG131.
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.
This guidance has been updated and replaced by NICE diagnostics guidance 32.
This guidance has been updated and replaced by NICE diagnostics guidance 34.
In development [GID-DT9] Expected publication date: TBC
In development [GID-DT14] Expected publication date: TBC
In development [GID-DT28] Expected publication date: TBC
In development [GID-MT516] Expected publication date: TBC
In March 2018, NICE reviewed this guidance and recommended it should be withdrawn as it has been updated and replaced by the NICE guideline on hypothermia: prevention and management in adults having surgery (NICE guideline CG65, updated 2016). For a copy of the review decision please contact nice@nice.org.uk.
In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.
In development [GID-MT267] Expected publication date: TBC
In development [GID-MT163] Expected publication date: TBC
In development [GID-MT81] Expected publication date: TBC
In March 2019, NICE reviewed this guidance and recommended it should be withdrawn because Vision Amniotic Leak Detector is no longer available. NICE has produced a medtech innovation briefing on AmnioSense for unexplained vaginal wetness in pregnancy. For a copy of the review decision, please contact nice@nice.org.uk.
In development [GID-MT517] Expected publication date: TBC
In development [GID-MT130] Expected publication date: TBC
In development [GID-MT117] Expected publication date: TBC
In development [GID-MT510] Expected publication date: TBC
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was